WALTHAM, Mass., Sept. 6, 2018 /PRNewswire/ -- Thermo Fisher
Scientific Inc. (NYSE: TMO), the world leader in serving science,
has signed a definitive agreement with BD (Becton, Dickinson and
Company – NYSE: BDX), a leading global medical technology company,
under which Thermo Fisher will
acquire BD's Advanced Bioprocessing business. This business
combines a strong technical services program with a variety of
peptones that enhance cell culture media formulations to improve
yield and reduce variability in biopharmaceutical applications.
"Thermo Fisher has a trusted
value proposition for customers who are working in biologic drug
development and manufacturing," said Mark
Stevenson, executive vice president and chief operating
officer of Thermo Fisher Scientific. "The addition of these new
capabilities will complement our bioproduction offering and
strengthen our ability to serve this rapidly growing market, from
development to large-scale production."
Patrick Kaltenbach, president of
Life Sciences for BD, said "We are excited that our Advanced
Bioprocessing team will have the opportunity to join a company with
deep expertise and a long-standing commitment to supporting
biopharmaceutical production. It will create new prospects,
building on a 25-year history of ensuring that high-quality
biopharmaceuticals get to the market quickly."
BD's Advanced Bioprocessing business has annualized revenue of
approximately $100 million and will
be integrated into Thermo Fisher's
Life Sciences Solutions Segment.
The transaction is subject to customary closing conditions and
is expected to close in early 2019.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world
leader in serving science, with revenues of more than
$20 billion and approximately
70,000 employees globally. Our mission is to enable our customers
to make the world healthier, cleaner and safer. We help our
customers accelerate life sciences research, solve complex
analytical challenges, improve patient diagnostics, deliver
medicines to market and increase laboratory productivity. Through
our premier brands – Thermo Scientific, Applied Biosystems,
Invitrogen, Fisher Scientific and Unity Lab Services – we offer an
unmatched combination of innovative technologies, purchasing
convenience and comprehensive support. For more information, please
visit www.thermofisher.com
Media Contact Information:
Karen Kirkwood, 781-622-1306
Email: karen.kirkwood@thermofisher.com
Website: www.thermofisher.com
or
Investor Contact Information:
Ken Apicerno, 781-622-1294
ken.apicerno@thermofisher.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/thermo-fisher-scientific-to-acquire-advanced-bioprocessing-business-from-bd-300708650.html
SOURCE Thermo Fisher Scientific